+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

LAG-3 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

LAG-3 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Tie-2 Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

Tie-2 Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Phaeochromocytoma - Pipeline Insight, 2025 - Product Thumbnail Image

Phaeochromocytoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
From
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
From
Mesothelioma - Pipeline Insight, 2025 - Product Thumbnail Image

Mesothelioma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Gastric Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Gastric Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 550 Pages
  • Global
From
Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 170 Pages
  • Global
From
Squamous Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Squamous Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
TCR Therapy- Pipeline Insight, 2025 - Product Thumbnail Image

TCR Therapy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Head And Neck Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
CAR-T - Pipeline Insight, 2025 - Product Thumbnail Image

CAR-T - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more